Member Exclusive

Overcoming the obstacles to a commercially successful cell or gene therapy: an interview with Dr Nafees Malik

In this interview, one of the world’s leading authorities on the commercialization of cell and gene therapies, Dr Nafees Malik, founder and CEO of Asklepian Consulting, explains the keys to successfully developing and commercializing a cell or gene product.

Go to the profile of Freya Leask
Jun 02, 2017
1
1

Please sign in or register for FREE

Register to RegMedNet

RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.

Register

1 Comments

Go to the profile of Lee Buckler
Lee Buckler about 2 months ago

I am always frustrated by the question: autologous vs allogeneic. There is plenty of room for both models in the future of medicine. Allogeneic cell therapy is easy to love from a business model perspective but it faces struggles when proving efficacy. The article seems to ignore all the investment and business enthusiasm for cell-based immunotherapy which is almost all based on use of autologous cells.